:’
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, continues to advance its neuroscience initiatives. With a focus on using nose-to-brain neurocircuitry, the company is developing intranasal product candidates known as pherines, targeting neurological and psychiatric conditions. Vistagen will disclose its fiscal year 2026 second-quarter financial results on November 13, 2025. Additionally, the company has presented new findings on Social Anxiety Disorder (SAD) and received a U.S. patent for AV-101 to tackle neuropathic pain, showcasing its commitment to addressing unmet needs in mental health and pain management.
Vistagen’s Financial Reporting and Conference Call:’
Located in South San Francisco, California, Vistagen announced it will host a conference call and webcast on November 13, 2025, to unveil its fiscal year 2026 second-quarter financial outcomes. This period, ending on September 30, 2025, marks an important phase in Vistagen’s strategic direction in pioneering innovative treatment methodologies. Stakeholders and interested parties are invited to engage with the company’s update at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), where company leadership will likely discuss progress, financials, and future projections.
Advancements in Social Anxiety Disorder Research:’
Continuing its pursuit of innovating treatments for psychiatric conditions, Vistagen recently shared groundbreaking research at the Anxiety and Depression Association of America (ADAA) 2025 Conference held in Las Vegas, Nevada. The company presented a series of poster sessions that delve into the age of onset for Social Anxiety Disorder (SAD) through patient data, providing insights that could refine therapeutic approaches. This contribution underscores the company’s commitment to enhancing the understanding of SAD, a condition with significant societal implications.
Patent Secured for Neuropathic Pain Treatment:’
In addition to its work on intranasal product lines, Vistagen secured a significant intellectual property milestone with the U.S. Patent and Trademark Office. The new patent covers AV-101, an oral non-opioid compound designed to treat neuropathic pain. The patent’s protection extends until at least 2034, fortifying Vistagen’s position in the pain management market. AV-101 represents Vistagen’s foray into addressing the challenges of pain treatment without resorting to opioid use, aligning with growing societal demands for non-addictive pain management alternatives.
Conclusion:’
Vistagen is at the forefront of neuroscientific innovation, with its diverse product pipeline and strategic research initiatives. The upcoming financial report is anticipated to provide investors and the broader scientific community with valuable insights into its operational health and ongoing projects. Moreover, its advancements in therapy for SAD and neuropathic pain highlight Vistagen’s integral role in reshaping future psychiatric and neurological care. These strategic moves solidify Vistagen’s influence in addressing some of the most pressing health issues of our time.
Comments